Franck S Rousseau

Summary

Affiliation: Gilead Sciences
Country: USA

Publications

  1. ncbi Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients
    Franck S Rousseau
    Triangle Pharmaceuticals, Durham, North Carolina 27717, USA
    J Infect Dis 188:1652-8. 2003
  2. ncbi Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection
    Laurene H Wang
    Gilead Sciences, Inc, Durham, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 20:1173-82. 2004
  3. ncbi Reproductive toxicology profile of emtricitabine in mice and rabbits
    George M Szczech
    Triangle Pharmaceuticals, Inc, 4611 University Drive, PO Box 50530, Durham, NC 27717, USA
    Reprod Toxicol 17:95-108. 2003
  4. ncbi Intracellular pharmacology of emtricitabine and tenofovir
    Robert C Stevens
    Clin Infect Dis 39:877-8; author reply 878-9. 2004
  5. ncbi Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Georgia, USA
    AIDS 19:1607-15. 2005

Collaborators

Detail Information

Publications5

  1. ncbi Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients
    Franck S Rousseau
    Triangle Pharmaceuticals, Durham, North Carolina 27717, USA
    J Infect Dis 188:1652-8. 2003
    ..The long plasma half-life and the superior antiviral activity versus 3TC of the 200 mg/day FTC dose confirmed the results of other studies and led to the selection of this dose for subsequent therapeutic trials...
  2. ncbi Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection
    Laurene H Wang
    Gilead Sciences, Inc, Durham, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 20:1173-82. 2004
    ..HIV RNA suppression (PD) correlates well with PBMC FTC-5'-TP levels (PK), both reaching a plateau at doses > or = 200 mg/day. The PK and PD characteristics of FTC demonstrate that it is a once daily nucleoside RT inhibitor...
  3. ncbi Reproductive toxicology profile of emtricitabine in mice and rabbits
    George M Szczech
    Triangle Pharmaceuticals, Inc, 4611 University Drive, PO Box 50530, Durham, NC 27717, USA
    Reprod Toxicol 17:95-108. 2003
    ..The development and fertility of F(1) progeny were unaffected by emtricitabine in a mouse pre- and post-natal study. These data demonstrate a favorable pre-clinical reproductive safety profile for emtricitabine...
  4. ncbi Intracellular pharmacology of emtricitabine and tenofovir
    Robert C Stevens
    Clin Infect Dis 39:877-8; author reply 878-9. 2004
  5. ncbi Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Georgia, USA
    AIDS 19:1607-15. 2005
    ..In ART-experienced patients, the antiviral activity was significant in those with no thymidine-analogue mutations and higher baseline CD4+ cell counts...